Table 3.
Number of days characterized by at least one common infectious disease (CID) symptom.
| Placebo | Probiotics | |||||
|---|---|---|---|---|---|---|
| Total | 0-28 d | 28-56 d | Total | 0-28 d | 28-56 d | |
| No. of days with at least one CID | 224a | 100 | 124b | 103a | 64 | 38b |
| No. of days with at least one RI | 87 | 71 | 54 | 20 | ||
| No. of days with at least one MS | 60 | 52 | 9 | 6 | ||
| No. of days with at least one GI | 13 | 31 | 8 | 12 | ||
Number of days characterized by at least one common infectious disease (CID) symptoms during the whole study (total), the treatment period (0-28 days), and the follow-up period (28-56 days). CID are differentiated into the following categories: respiratory symptoms (RI), musculoskeletal symptoms (MS), and gastrointestinal (GI) symptoms. The number of days with CIDs was compared between groups using the Wilcoxon test (with False Discovery Rate adjustment for multiple comparisons for the analysis by study periods). Statistically significant results are reported in bold (p value < 0.01). aIndicates the comparison “total in the placebo group” vs. “total in the probiotic group”; bindicates the comparison “follow-up in the placebo group” vs. “follow-up in the probiotic group”.